<DOC>
	<DOCNO>NCT01492543</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety profile Aiyi® ( Tegafur Gimeracil Oteracil Potassium Capsule , TS-1 ) second line therapy Chinese female patient advance metastatic breast cancer .</brief_summary>
	<brief_title>Study TS-1 2nd Line Treatment Patients With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>Tegafur Gimeracil Oteracil Potassium Capsule novel oral derivative 5-fluorouracil ( 5-FU ) prodrug tegafur combine two modulators . Recent clinical trial report promising effect Tegafur Gimeracil Oteracil Potassium Capsule metastatic breast cancer . The innovative drug , S-1 , obtain approval treatment advance breast cancer Japan , meanwhile , Generic drug approve indication gastric cancer China mainland Chinese authority , SFDA , Chinese clinical study data TS-1 breast cancer far .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Age : 1875 year old female . ECOG status : 02 . Life expectancy ≥ 3 month . Histologic cytologic diagnosis breast cancer . Progression receive one standard prior chemotherapy regimen recurrent metastatic lesion except endocrine regimen . At least one measurable lesion &gt; =2 cm ( &gt; =1 cm spiral CT scan ) accord RECIST ( v1.1 ) . Adequate organ function : Hematopoietic : Hemoglobin ≥90g/L , Absolute neutrophil count ≥1.5×10^9/L , Platelet count ≥80×10^9/L . Biochemistry : TBil ≤1.5 time upper limit normal ( ULN ) , AST ALT ≤2.5× ULN ( ≤5x ULN due liver metastasis ) , Creatinine ≤1.0×ULN Creatinine clearance &gt; 50 ml/min . Women child potential must negative pregnancy test 7 day prior enrollment willing practice acceptable method birth control study 8 week last drug administer . Ability take oral medication . Signed informed consent . Pregnancy lactation effective contraception fertile patient . Prior treatment 5FU drug class ( exclude patient relapse one year adjuvant therapy ) . Less 4 week since prior investigational agent . condition impact oral drug take absorption ( e.g . inability swallow , gastrointestinal resection , chronic diarrhea , intestinal obstruction ) . Organ invasion rapid progression ( e.g . lesion exceed half Liver Lung ) . CNS psychiatric disorder . Allergic 5FU . Only bone metastases measurable lesion . Clinically significant heart disease ( e.g.congestive heart failure , ventricular arrhythmia , myocardial infarction ) enrollment . Serious peptic ulcer disease digestive disorder . Bone marrow ( Hemoglobin &lt; 90g/dl , ANC &lt; 1.5×10^9/L , Platelet count &lt; 75×10^9/L ) . Renal function disorder ( Creatinine &gt; 1.0×ULN ) . Liver function disorder ( TBil &gt; 1.5×ULN ) . Uncontrolled brain metastasis . Noncompliance study protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Breast cancer</keyword>
</DOC>